Guardant Health, Inc. (GH)
CIK 1576280 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 134.2M shares as of Jul 24, 2026 (10-Q).
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
Warrants outstanding: 0 underlying shares, as reported Dec 31, 2020 (10-K).
Reported exercise price: $0.14 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 134.2M = 134.2M O/S + 0 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Convertible Senior Notes Due 2031 | $600.0M | $622.7M | $62.22 | 1.25% | ~9.6M sh |
| Convertible Senior Notes Due 2027 | $490.7M | $490.7M | $46.09 | 0% | ~10.6M sh |
| Convertible Senior Notes Due 2033 | $402.5M | $391.2M | $121.5 | 0% | ~3.3M sh |
If every note above converted at its tagged price: ~23.6M new shares on 134.2M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Jul 30, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 134.2M | Jul 24, 2026 |
| + Warrants (aggregate, as tagged) (if exercised) | 0 | Dec 31, 2020 |
| + Convertible Senior Notes Due 2031 (if fully converted) | 9.6M | Jun 30, 2026 |
| + Convertible Senior Notes Due 2027 (if fully converted) | 10.6M | Jun 30, 2026 |
| + Convertible Senior Notes Due 2033 (if fully converted) | 3.3M | Jun 30, 2026 |
| Fully diluted estimate | 157.8M | +17.6% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 3 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full GH workspace